| 吾尔娜,裴斐菲,史名杨,哈斯也提·依不拉音,刘海英.阿替普酶静脉溶栓治疗AIS患者短期不良反应观察.[J].中南医学科学杂志.,2023,(6):901-903. |
| 阿替普酶静脉溶栓治疗AIS患者短期不良反应观察 |
| Observation of short-term untoward effect of intravenous thrombolytic therapy with alteplase in AIS patients |
| 投稿时间：2023-01-12 修订日期：2023-07-21 |
| DOI：10.15972/j.cnki.43-1509/r.2023.06.024 |
| 中文关键词: 阿替普酶 急性缺血性脑卒中 不良反应 [ |
| 英文关键词:alteplase acute ischemic stroke untoward effect |
| 基金项目:新疆神经系统疾病研究重点实验室开放课题(XJDX1711-2122) |
|
| 摘要点击次数: 184 |
| 全文下载次数: 206 |
| 中文摘要: |
| 目的观察阿替普酶静脉溶栓治疗急性缺血性脑卒中(AIS)患者短期不良反应。 方法回顾性分析本院阿替普酶静脉溶栓治疗AIS患者200例的临床资料。记录患者治疗后临床疗效、治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分以及不良反应发生情况。将未出现不良反应的患者纳入未发生组,出现不良反应的患者纳入发生组。比较两组临床资料,并分析患者出现短期不良反应的影响因素。 结果患者治疗后临床总有效率为90.5%,治疗后7天内不良反应发生率为21.0%。患者治疗后7天NIHSS评分较治疗前明显降低(P＜0.05)。未发生组与发生组患者年龄、高血压史比较,差异有显著性(P＜0.05)。AIS患者出现短期不良反应与年龄、高血压史有关(P＜0.05)。多因素Logistic回归分析结果显示,年龄大、患有高血压是AIS患者发生短期不良反应的危险因素。 结论阿替普酶静脉溶栓治疗AIS,具有较好的临床疗效且患者的不良反应发生率较低。 |
| 英文摘要: |
| AimTo observe the short-term untoward effect of intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke (AIS). MethodsThe clinical data of 200 AIS patients who were treated with alteplase intravenous thrombolysis were retrospectively analyzed. The clinical efficacy, national institutes of health stroke scale (NIHSS) score before and after treatment, and the occurrence of adverse reactions were recorded. Patients with no adverse reactions were included in the no-occurrence group, and patients with adverse reactions were included in the occurrence group. The clinical data of the two groups were compared, and the influencing factors of short-term adverse reactions were analyzed. ResultsThe total clinical effective rate was 90.5%, and the occurrence of untoward effect within 7 days after therapy was 21.0%.The NIHSS score at 7 days after therapy was evidently lower than that before therapy (P＜0.05). There were significant differences in age and history of hypertension between the no-occurrence group and the occurrence group (P＜0.05). The short-term untoward effect of AIS patients was related to age and history of hypertension (P＜0.05). Multivariate Logistic regression analysis showed that old age and hypertension are risk factors for short-term adverse reactions in AIS patients. ConclusionAlteplase intravenous thrombolytic therapy for AIS has good clinical efficacy and low incidence of adverse reactions in patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|